Theralink’s Exclusive Licensed RPPA Technology for Commercial Laboratory Testing to Assist the White House Cancer Moonshot Initiative
Golden, Colorado — January 17, 2023 — Theralink Technologies (OTC: THER) (“Theralink” or the “Company”), a precision oncology company with a novel quantitative protein and phosphoprotein-based assay for breast cancer, today announced its support of George Mason University’s involvement in the White House Cancer Moonshot Initiative. Mick Ruxin, M.D., Chief Executive Officer of Theralink said, […]
Theralink® Technologies Appoints Michael Vallone as Senior Director of Commercialization
Mr. Vallone’s Appointment Supports the Company’s Shift from R&D to a Commercially Driven Enterprise GOLDEN, Colo., Jan. 9, 2023 /PRNewswire/ — Theralink Technologies (OTC: THER) (“Theralink” or the “Company”), a precision oncology company with a novel quantitative protein and phosphoprotein-based assay for breast cancer, today announced the appointment of Michael Vallone as Senior Director of Commercialization. Faith Zaslavsky, President & Chief Operating Officer of […]
Theralink® Technologies Appoints Seasoned Commercial Leader, Faith Zaslavsky, as President & Chief Operating Officer for its Precision Oncology Company
Faith, a Seasoned Genomics Commercial Leader with a Special Interest in Reverse Phase Protein Array Technology and Biomarkers, will Lead Theralink’s Commercialization Strategy Golden, Colorado — December 6, 2022 — Theralink Technologies (OTC: THER) (“Theralink” or the “Company”), the only US precision oncology company with commercial RPPA technology that can tell which FDA-approved drug is […]
Theralink® Technologies Accepted to Present Two Posters at the Upcoming San Antonio Breast Cancer Symposium
Presented findings highlight the unique insights that Theralink’s Assay generates to advance breast cancer research and care Golden, Colorado — December 1, 2022 — Theralink Technologies (OTC: THER) (“Theralink” or the “Company”), a precision oncology company with a novel quantitative protein and phosphoprotein-based assay for breast cancer, today announced the acceptance of two poster presentations […]